A new, validated HPLC-MS/MS method for the simultaneous determination of the anti-cancer agent capecitabine and its metabolites: 5′-deoxy-5- fluorocytidine, 5′-deoxy-5-fluorouridine, 5-fluorouracil and 5-fluorodihydrouracil, in human plasma

Biomedical Chromatography

Volumn 24, Issue 4, 2010, Pages 374-386

  Vainchtein, Liia D ^a,b   Rosing, Hilde ^c   Schellens, Jan H M ^d,e   Beijnen, Jos H ^c,d,e  

^a Astellas Pharma Global Development   (Netherlands)

^b Netherlands Cancer Institute ^*  (Netherlands)

^c SLOTERVAART HOSPITAL   (Netherlands)

^d UTRECHT UNIVERSITY   (Netherlands)

^e ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

Author keywords

5 FU; Capecitabine; Hypercarb; Liquid chromatography; Mass spectrometry; Metabolites

Indexed keywords

BIOMOLECULES; ELECTROSPRAY IONIZATION; HIGH PRESSURE LIQUID CHROMATOGRAPHY; METABOLITES; PLASMA (HUMAN); POROUS MATERIALS; PRECIPITATION (CHEMICAL); TRICHLOROACETIC ACID;

5-FLUORODIHYDROURACIL; 5-FLUOROURACIL; ANTI-CANCER AGENTS; CAPECITABINE; CV VALUE; HPLC-MS-MS; HUMAN PLASMAS; HYPERCARB; SELECTIVE LIQUID CHROMATOGRAPHY; SIMULTANEOUS DETERMINATIONS;

MASS SPECTROMETRY;

2 PROPANOL; 5 CHLOROURACIL DERIVATIVE; 5' DEOXY 5 FLUOROCYTIDINE; ACETONITRILE; AMMONIUM ACETATE; CAPECITABINE; DIHYDROFLUOROURACIL; DOXIFLURIDINE; FLUDARABINE; FLUOROURACIL; TETRAHYDROFURAN; TRICHLOROACETIC ACID;

ARTICLE; CONTROLLED STUDY; ELECTROSPRAY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; PRECIPITATION; TANDEM MASS SPECTROMETRY;

EID: 77950204871     PISSN: 02693879     EISSN: 10990801     Source Type: Journal    
DOI: 10.1002/bmc.1302     Document Type: Article

References (45)

1. Antonio C, Larson T, Gilday A, Graham I, Bergstrom E and Thomas-Oates J. Quantification of sugars and sugar phosphates in Arabidopsis thaliana tissues using porous graphitic carbon liquid chromatography-electrospray ionization mass spectrometry. Journal of Chromatography A 2007; 1172: 170-178.
2. Ayrton J, Evans MB, Harris AJ and Plumb RS. Porous graphitic carbon shows promise for the rapid chromatographic analysis of polar drug metabolites. Journal of Chromatography B: Biomedical Sciences and Applications 1995; 667: 173-178.
3. Bohnstedt KC, Karlberg B, Basun H and Schmidt S. Porous graphitic carbon chromatography-tandem mass spectrometry for the study of isoprostanes in human cerebrospinal fluid. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences 2005; 827: 39-43.
4. Braun AH, Achterrath W, Wilke H, Vanhoefer U, Harstrick A and Preusser P. New systemic frontline treatment for metastatic colorectal carcinoma. Cancer 2004; 100: 1558-1577.
5. Cantu R, Evans O, Kawahara FK, Wymer LJ and Dufour AP. HPLC determination of cyanuric acid in swimming pool waters using phenyl and confirmatory porous graphitic carbon columns. Analyical Chemistry 2001; 73: 3358-3364.
6. Cassidy J, Twelves C, Cameron D, Steward W, O'Byrne K, Jodrell D, Banken L, Goggin T, Jones D, Roos B, Bush E, Weidekamm E and Reigner B. Bioequivalence of two tablet formulations of capecitabine and exploration of age, gender, body surface area, and creatinine clearance as factors influencing systemic exposure in cancer patients. Cancer Chemotherapy and Pharmacology 1999; 44: 453-460.
7. Desmoulin F, Gilard V, Malet-Martino M and Martino R. Metabolism of capecitabine, an oral fluorouracil prodrug: (19)F NMR studies in animal models and human urine. Drug Metabolism and Disposition 2002; 30: 1221-1229.
8. Dhananjeyan MR, Liu J, Bykowski C, Trendel JA, Sarver JG, Ando H and Erhardt PW. Rapid and simultaneous determination of capecitabine and its metabolites in mouse plasma, mouse serum, and in rabbit bile by high-performance liquid chromatography. Journal of Chromatography A 2007; 1138: 101-108.
9. Etienne MC, Lagrange JL, Dassonville O, Fleming R, Thyss A, Renee N, Schneider M, Demard F and Milano G. Population study of dihydropyrimidine dehydrogenase in cancer patients. Journal of Clinical Oncology 1994; 12: 2248-2253.
10. Fleming RA, Milano GA, Gaspard MH, Bargnoux PJ, Thyss A, Plagne R, Renee N, Schneider M and Demard F. Dihydropyrimidine dehydrogenase activity in cancer patients. European Journal of Cancer 1993; 29A: 740-744.
11. Gamelin E, Boisdron-Celle M, Delva R, Regimbeau C, Cailleux PE, Alleaume C, Maillet ML, Goudier MJ, Sire M, Person-Joly MC, Maigre M, Maillart P, Fety R, Burtin P, Lortholary A, Dumesnil Y, Picon L, Geslin J, Gesta P, Danquechin Dorval E, Larra F and Robert J. Long-term weekly treatment of colorectal metastatic cancer with fluorouracil and leucovorin: results of a multicentric prospective trial of fluorouracil dosage optimization by pharmacokinetic monitoring in 152 patients. Journal of Clinical Oncology 1998; 16: 1470-1478.
12. Gaudin K, Chaminade P and Baillet A. Eluotropic strength in non-aqueous liquid chromatography with porous graphitic carbon. Journal of Chromatography A 2002; 973: 61-68.
13. Grem J L. 5-Fluorouracil: forty-plus and still ticking. A review of its preclinical and clinical development. Investigational New Drugs 2000; 18: 299-313.
14. Gu GH and Lim CK. Separation of anionic and cationic compounds of biomedical interest by high-performance liquid chromatography on porous graphitic carbon. Journal of Chromatography A 1990; 515: 183-192.
15. Guichard SM, Mayer I and Jodrell DI. Simultaneous determination of capecitabine and its metabolites by HPLC and mass spectrometry for preclinical and clinical studies Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences 2005; 826: 232-237.
16. Hanai T. Separation of polar compounds using carbon columns. Journal of Chromatography A 2003; 989: 183-196.
17. Holmgren E, Carlsson H, Goede P and Crescenzi C. Determination and characterization of organic explosives using porous graphitic carbon and liquid chromatography-atmospheric pressure chemical ionization mass spectrometry. Journal of Chromatography A 2005; 1099: 127-135.
18. Jackson PT and Carr PW. Study of polar and nonpolar substituted benzenes and aromatic isomers on carbon-coated zirconia and alkyl bonded phases. Journal of Chromatography A 2002; 958: 121-129.
19. 14C-labelled drug. Investigational New Drugs 1999; 17: 49-56.
20. Lepont C, Gunatillaka AD and Poole CF. Retention characteristics of porous graphitic carbon in reversed-phase liquid chromatography with methanol-water mobile phases. Analyst 2001; 126: 1318-1325.
21. Lu Z, Zhang R and Diasio RB. Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy. Cancer Research 1993; 53: 5433-5438.
22. Mader RM, Muller M and Steger GG. Resistance to 5-fluorouracil. General Pharmacology 1998; 31: 661-666.
23. Malet-Martino M and Martino R. Clinical studies of three oral prodrugs of 5-fluorouracil (capecitabine, UFT, S-1): a review. Oncologist 2002; 7: 288-323.
24. Matuszewski BK, Constanzer ML and Chavez-Eng CM. Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS. Analytical Chemistry 2003; 75: 3019-3030.
25. Mazan S, Cretier G, Gilon N, Mermet JM and Rocca JL. Porous graphitic carbon as stationary phase for LC-ICPMS separation of arsenic compounds in water. Analytical Chemistry 2002; 74: 1281-1287.
26. Merelli B, De PM, Favetta P and Lafosse M. Analysis of triacylglycerols on porous graphitic carbon by high temperature liquid chromatography. Journal of Chromatography A 2007; 1157: 462-466.
27. Ninomiya Y, Miwa M, Eda H, Sahara H, Fujimoto K, Ishida M, Umeda I, Yokose K and Ishitsuka H. Comparative antitumor activity and intestinal toxicity of 5′-deoxy-5-fluorouridine and its prodrug trimethoxybenzoyl-5′- deoxy-5-fluorocytidine. Japanese Journal of Cancer Research 1990; 81: 188-195.
28. Pereira L, Aspey S and Ritchie H. High temperature to increase throughput in liquid chromatography and liquid chromatography-mass spectrometry with a porous graphitic carbon stationary phase. Journal of Separation Science 2007; 30: 1115-1124.
29. Polson C, Sarkar P, Incledon B, Raguvaran V and Grant R. Optimization of protein precipitation based upon effectiveness of protein removal and ionization effect in liquid chromatography-tandem mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences 2003; 785: 263-275.
30. Reepmeyer JC, Brower JF and Ye H. Separation and detection of the isomeric equine conjugated estrogens, equilin sulfate and delta8,9- dehydroestrone sulfate, by liquid chromatography-electrospray-mass spectrometry using carbon-coated zirconia and porous graphitic carbon stationary phases. Journal of Chromatography A 2005; 1083: 42-51.
31. Reigner B, Verweij J, Dirix L, Cassidy J, Twelves C, Allman D, Weidekamm E, Roos B, Banken L, Utoh M and Osterwalder B. Effect of food on the pharmacokinetics of capecitabine and its metabolites following oral administration in cancer patients. Clinical Cancer Research 1998; 4: 941-948.
32. Reigner B, Clive S, Cassidy J, Jodrell D, Schulz R, Goggin T, Banken L, Roos B, Utoh M, Mulligan T and Weidekamm E. Influence of the antacid Maalox on the pharmacokinetics of capecitabine in cancer patients. Cancer Chemotherapy and Pharmacology 1999; 43: 309-315.
33. Remaud G, Boisdron-Celle M, Hameline C, Morel A and Gamelin E. An accurate dihydrouracil/uracil determination using improved high performance liquid chromatography method for preventing fluoropyrimidines- related toxicity in clinical practice. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences 2005; 823: 98-107.
34. Rosing H, Man W, Doyle E, Bult A and Beijnen JH. Bioanalytical liquid chromatographic method validation: a review of current practices and procedures. Journal of Liquid Chromatography and Related Technologies 2000; 329-341.
35. Roy S, Delobel A, Gaudin K, Touboul D, Germain DP, Baillet A, Prognon P, Laprevote O and Chaminade P. Liquid chromatography on porous graphitic carbon with atmospheric pressure photoionization mass spectrometry and tandem mass spectrometry for the analysis of glycosphingolipids. Journal of Chromatography A 2006; 1117: 154-162.
36. SiethoffC, Orth M, Ortling A, Brendel E and Wagner-Redeker W. Simultaneous determination of capecitabine and its metabolite 5-fluorouracil by column switching and liquid chromatographic/tandem mass spectrometry. Jounal of Mass Spectrometry 2004; 39: 884-889.
37. Tabata T, Katoh M, Tokudome S, Hosakawa M, Chiba K, Nakajima M and Yokoi T. Bioactivation of capecitabine in human liver: involvement of the cytosolic enzyme on 5′-deoxy-5-fluorocytidine formation. Drug Metabolism and Disposition 2004; 32: 762-767.
38. Tachon R, Pichon V, Le Borgne MB and Minet JJ. Use of porous graphitic carbon for the analysis of nitrate ester, nitramine and nitroaromatic explosives and by-products by liquid chromatography-atmospheric pressure chemical ionisation-mass spectrometry. Journal of Chromatography A 2007; 1154: 174-181.
39. Thiebaut D, Vial J, Michel M, Hennion MC and Greibrokk T. Evaluation of reversed phase columns designed for polar compounds and porous graphitic carbon in 'trapping' and separating neurotransmitters. Journal of Chromatography A 2006; 1122: 97-104.
40. US Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for Industry. Bioanalytical Method Validation. Available at: www fda gov/cder/quidance/4252fnl htm 2001.
41. Vial J, Hennion MC, Fernandez-Alba A and Aguera A. Use of porous graphitic carbon coupled with mass detection for the analysis of polar phenolic compounds by liquid chromatography. Journal of Chromatography A 2001; 937: 21-29.
42. Xia YQ, Jemal M, Zheng N and Shen X. Utility of porous graphitic carbon stationary phase in quantitative liquid chromatography/tandem mass spectrometry bioanalysis: quantitation of diastereomers in plasma. Rapid Communications in Mass Spectrometry 2006; 20: 1831-1837.
43. Xing J, Apedo A, Tymiak A and Zhao N. Liquid chromatographic analysis of nucleosides and their mono-, di- and triphosphates using porous graphitic carbon stationary phase coupled with electrospray mass spectrometry. Rapid Communications in Mass Spectrometry 2004; 18: 1599-1606.
44. Xu Y and Grem JL. Liquid chromatography-mass spectrometry method for the analysis of the anti-cancer agent capecitabine and its nucleoside metabolites in human plasma. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences 2003; 783: 273-285.
45. Zufia L, Aldaz A and Giraldez J. Simple determination of capecitabine and its metabolites by liquid chromatography with ultraviolet detection in a single injection. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences 2004; 809: 51-58.